The cash runway guidance ($47-50M by June 2026) implies the company will need to raise capital or secure a partnership within the next 6-12 months, absent a clinical hold resolution. The FDA clinical hold on simufilam is the single most important catalyst — monitor for any regulatory updates or data submissions. The $31.25M litigation settlement payment is a near-term cash drain with no offsetting revenue.
Price Chart
Executive Summary
Filana Therapeutics (FLNA) reported Q1 2026 results with a net loss of $10.3M ($0.21/share), narrower than the $23.4M loss in Q1 2025, driven by the phase-out of the Alzheimer's program. Cash burn remains the primary concern: cash dropped from $95.5M (Dec 2025) to $86.6M, and management guided cash to $47-50M by June 2026, implying a ~$39M quarterly burn rate that includes a $31.25M litigation settlement payment. The company remains under an FDA clinical hold for its sole pipeline asset simufilam, with no timeline for resolution.
Key Financial Metrics
Key Facts
- Net loss of $10.3M ($0.21/share) vs $23.4M ($0.48/share) in Q1 2025 — narrower loss due to Alzheimer's program wind-down
- Cash and equivalents at $86.6M as of March 31, 2026, down from $95.5M at Dec 31, 2025
- Company estimates cash at June 30, 2026 in a range of $47-50M, implying ~$39M quarterly cash burn including a $31.25M litigation settlement payment
- FDA clinical hold on simufilam IND for TSC-related epilepsy remains unresolved — no timeline for resolution provided
- R&D expenses fell 67% YoY to $4.5M due to Alzheimer's program phase-out; G&A fell 39% to $6.6M
- No revenue, no approved products, and no near-term catalyst to resolve the clinical hold
Financial Impact
Cash burn of ~$39M in Q1 2026 (including $31.25M litigation settlement) leaves runway of ~2 quarters at current burn rate; cash guided to $47-50M by June 2026
Risk Factors
- FDA clinical hold on simufilam IND with no resolution timeline — could delay or kill the program
- Cash runway of ~2 quarters at current burn rate after June 2026 — likely requires dilutive financing
- No approved products or revenue — entirely dependent on successful clinical development
- Potential $31.25M litigation settlement payment further strains cash position
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003119 |
| Document: f8k_050726.htm | 0001171843-26-003119 |
| Document: 0001171843-26-003119-index-headers.html | 0001171843-26-003119 |
| Document: 0001171843-26-003119-index.html | 0001171843-26-003119 |
| Document: 0001171843-26-003119.txt | 0001171843-26-003119 |
| 8-K Data (Synthetic) | 0001171843-26-003119 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $0.6885 | awaiting T+20 | — | $0.6483 (−5.84%) |
Sep 22, 2026 5w ago | 8-K | $1.03 $0.6900 | ▼ −33.01% | ▼ −32.45% | $0.6483 (−37.06%) |
Sep 18, 2026 5w ago | 8-K | $0.7395 $0.6820 | ▲ +7.78% | ▲ +6.87% | $0.6483 (+12.33%) |
Jul 29, 2026 12w ago | 8-K | $0.8696 $0.9244 | ▲ +6.30% | ▲ +1.28% | $0.6483 (−25.45%) |
Jun 15, 2026 19w ago | 8-K | $1.21 $1.15 | ▼ −4.96% | ▼ −4.21% | $0.6483 (−46.42%) |
May 7, 2026 24w ago | 8-K | $1.36 $1.36 | · 0.00% | ▲ +3.14% | $0.6483 (+52.33%) |
May 7, 2026 24w ago | Press Release | $1.36 $1.36 | · 0.00% | ▼ −3.14% | $0.6483 (−52.33%) |
Mar 12, 2026 32w ago | Press Release | $1.95 $1.64 | ▲ +15.90% | ▲ +17.87% | $0.6483 (+66.75%) |
Mar 10, 2026 33w ago | 8-K | $2.38 $1.70 | ▼ −28.57% | ▼ −28.42% | $0.6483 (−72.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers